CEL-SCI Corporation Reports Decreased Net Loss and Focus on Multikine Clinical Trials

CEL-SCI Corporation reported its financial results for the three months ending December 31, 2025, revealing a net loss of $5.5 million, a decrease from the $7.1 million loss recorded in the same period the previous year. The company’s operating expenses totaled $5.4 million, down from $6.9 million in the prior year, primarily due to reduced research and development costs, which fell to $3.7 million from $4.4 million. General and administrative expenses also decreased significantly, from $2.5 million to $1.7 million, reflecting cost-cutting measures and a reduction in public relations expenses.

In terms of liquidity, CEL-SCI's cash and cash equivalents decreased to $6.3 million as of December 31, 2025, down from $11 million at the end of the previous fiscal quarter. The company’s total assets also declined to $22.9 million from $28.2 million, while total liabilities decreased slightly to $11.8 million. The reduction in cash was attributed to operational expenditures and payments on finance lease obligations. The company has expressed substantial doubt about its ability to continue as a going concern, emphasizing the need for additional capital to support ongoing research and development efforts.

Strategically, CEL-SCI is focused on advancing its lead investigational therapy, Multikine, which is currently in Phase 3 clinical trials for the treatment of advanced primary head and neck cancer. The company has completed a bias analysis for the target population and is preparing for a confirmatory registration study, which is expected to enroll 212 patients. The Phase 3 study results indicated a 73% survival rate for patients treated with Multikine compared to 45% for those receiving standard care, highlighting the potential efficacy of the therapy.

Operationally, CEL-SCI has made significant strides in its clinical development, with approximately 740 patients having been treated in various studies. The company has also engaged Ergomed Clinical Research, Inc. for clinical development services, incurring approximately $0.7 million in related expenses. As of December 31, 2025, CEL-SCI's employee headcount remained stable, and the company continues to explore partnerships and financing options to support its clinical trials and operational needs.

Looking ahead, CEL-SCI aims to raise additional capital to fund the confirmatory study and other operational costs. The estimated cost of the confirmatory registration study is projected to be between $30 million and $35 million. The company remains optimistic about its ability to secure funding, citing past successes in raising capital, but acknowledges the uncertainty surrounding market conditions and regulatory approvals. The future of CEL-SCI hinges on the successful completion of its clinical trials and the potential approval of Multikine, which could address a significant unmet medical need in cancer treatment.